| Literature DB >> 31998728 |
Jiajia Ye1,2, Michael William Simpson2, Yang Liu3, Wei Lin4, Weihong Zhong1, Shuhe Cai5,6, Liye Zou7.
Abstract
Background: Knee osteoarthritis is a common disease affecting a large number of old individuals worldwide. This study aimed to explore the effects of Baduanjin Qigong in patients with knee osteoarthritis.Entities:
Keywords: Baduanjin; Qigong; exercise; mind-body exercise; osteoarthritis; postural stability; proprioception
Year: 2020 PMID: 31998728 PMCID: PMC6966958 DOI: 10.3389/fmed.2019.00307
Source DB: PubMed Journal: Front Med (Lausanne) ISSN: 2296-858X
Demographic data of participants.
| Age, year | 64.48 ± 7.81 | 63.08 ± 3.65 | 0.412 |
| Height, cm | 163.28 ± 7.83 | 161.92 ± 7.56 | 0.535 |
| Weight, kg | 64.60 ± 9.19 | 64.20 ± 5.70 | 0.854 |
| Body mass index, kg/m2 | 24.15 ± 2.47 | 24.56 ± 2.31 | 0.553 |
BD, Baduanjin group; CG, control group.
Figure 1Flow chart of the progress of all procedure.
Mean ± SD performance value of postural stability, proprioception, and WOMAC.
| BD | 4.92 ± 0.91 | 0.184 | 4.67 ± 1.23 | 4.71 ± 1.54 | 0.754 | 0.588 | 0.440 | 0.760 | 0.016 |
| CG | 4.60 ± 0.76 | 4.56 ± 1.29 | 5.08 ± 2.00 | ||||||
| BD | 4.44 ± 1.12 | 0.223 | 4.04 ± 0.94 | 4.36 ± 2.12 | 0.850 | 0.301 | 0.373 | 0.931 | 0.019 |
| CG | 4.00 ± 1.38 | 4.16 ± 1.03 | 4.84 ± 2.09 | ||||||
| BD | 6.28 ± 1.72 | 0.769 | 5.48 ± 0.96 | 5.44 ± 1.26 | 0.006 | 0.217 | 0.035 | 3.459 | 0.067 |
| CG | 6.16 ± 1.07 | 6.08 ± 1.12 | 6.64 ± 1.11 | ||||||
| BD | 5.96 ± 1.74 | 0.928 | 5.64 ± 1.58 | 5.56 ± 1.08 | 0.093 | 0.993 | 0.376 | 0.987 | 0.020 |
| CG | 5.92 ± 1.32 | 6.282.37 | 6.40 ± 1.61 | ||||||
| BD | 43.84 ± 10.84 | 0.500 | 38.52 ± 12.13 | 31.16 ± 6.81 | 0.023 | 0.001 | 0.029 | 3.699 | 0.071 |
| CG | 41.96 ± 8.61 | 43.40 ± 11.84 | 39.64 ± 7.11 | ||||||
| BD | 58.56 ± 17.99 | 0.093 | 37.60 ± 17.08 | 43.20 ± 20.64 | 0.001 | 0.001 | 0.144 | 1.977 | 0.040 |
| CG | 66.84 ± 16.12 | 57.56 ± 13.76 | 54.00 ± 12.37 | ||||||
| BD | 31.94 ± 12.32 | 0.523 | 20.08 ± 9.95 | 14.52 ± 6.17 | 0.003 | 0.001 | 0.001 | 19.572 | 0.290 |
| CG | 29.24 ± 11.41 | 30.16 ± 10.95 | 28.28 ± 8.40 | ||||||
| BD | 6.64 ± 2.74 | 0.528 | 2.88 ± 1.54 | 3.68 ± 6.07 | 0.015 | 0.011 | 0.357 | 0.988 | 0.020 |
| CG | 7.68 ± 9.34 | 6.48 ± 2.37 | 4.92 ± 1.41 | ||||||
| BD | 4.16 ± 2.14 | 0.757 | 2.04 ± 1.43 | 2.32 ± 1.38 | 0.001 | 0.686 | 0.001 | 31.248 | 0.390 |
| CG | 4.32 ± 1.44 | 7.00 ± 2.63 | 6.40 ± 2.04 | ||||||
| BD | 20.84 ± 11.04 | 0.529 | 15.64 ± 8.87 | 9.52 ± 6.04 | 0.271 | 0.001 | 0.005 | 5.679 | 0.106 |
| CG | 19.08 ± 8.41 | 17.00 ± 8.71 | 16.24 ± 6.82 | ||||||
OP, open eyes; AP, anteroposterior; ML, mediolateral; CP, closed eyes; TTE, test time execution; ATE, average trace error; SD, standard deviation; BD, Baduanjin group; CG, control group; WOMAC, the Western Ontario and McMaster Universities Osteoarthritis Index.
Denotes a significant effect (P < 0.05).
Results of outcome variables with post-hoc analysis over time in both groups.
| OPAP | 0.557 | 0.900 | 1.00 | 0.303 | 0.656 | 0.247 | |
| (mm) | 95% CI | −0.40 to 0.72 | −0.61 to 0.69 | −0.95 to 0.95 | −1.54 to 0.50 | −0.57 to 0.89 | −1.32 to 0.36 |
| OPML | 0.187 | 0.632 | 0.513 | 0.223 | 0.868 | 0.215 | |
| (mm) | 95% CI | −0.21 to 1.00 | −0.84 to 0.52 | −1.32 to 0.68 | −1.80 to 0.44 | −0.91 to 1.06 | −2.20 to 0.52 |
| CPAP | 0.030 | 0.817 | 0.908 | 0.100 | 0.074 | 0.130 | |
| (mm) | 95% CI | 0.09 to 1.52 | −0.62 to 0.78 | −0.67 to 0.75 | −1.24 to 0.12 | −0.09 to 1.77 | −1.11 to 0.15 |
| CPML | 0.476 | 0.519 | 0.853 | 0.827 | 0.266 | 0.286 | |
| (mm) | 95% CI | −0.59 to 1.23 | −1.50 to 0.78 | −0.80 to 0.96 | −1.24 to 1.00 | −0.33 to 1.13 | −1.39 to 0.43 |
| TTE (s) | 0.125 | 0.617 | 0.010 | 0.151 | 0.001 | 0.361 | |
| 95% CI | −1.59 to 12.23 | 7.31 to 4.43 | 7.47 to 17.89 | −2.82 to 7.46 | 1.93 to 12.79 | −1.47 to 8.99 | |
| ATE (%) | 0.001 | 0.029 | 0.277 | 0.331 | 0.001 | 0.018 | |
| 95% CI | 11.19 to 30.73 | 1.03 to 17.53 | 4.80 to −1.11 | −3.85 to 10.97 | 8.03 to 22.69 | 2.44 to 23.24 | |
| Overall | 0.001 | 0.703 | 0.009 | 0.152 | 0.001 | 0.696 | |
| WOMAC | 95% CI | 6.68 to 15.96 | −5.85 to 4.01 | 1.49 to 9.63 | −0.74 to 4.50 | 13.38 to 20.38 | −4.04 to 5.96 |
| Pain | 0.001 | 0.541 | 0.530 | 0.003 | 0.049 | 0.161 | |
| 95% CI | 2.40 to 4.72 | −2.80 to 5.20 | −3.39 to 1.79 | 0.60 to 2.52 | 0.02 to 5.50 | −1.18 to 6.70 | |
| Stiffness | 0.001 | 0.001 | 0.436 | 0.321 | 0.001 | 0.001 | |
| 95% CI | 1.20 to 3.05 | −3.71 to −1.65 | −1.01 to 0.45 | −0.62 to 1.82 | 0.99 to 2.69 | −2.91 to −1.26 | |
| Physical function | 0.014 | 0.300 | 0.002 | 0.607 | 0.001 | 0.176 | |
| 95% CI | 1.18 to 9.23 | −1.98 to 6.14 | 2.36 to 9.86 | −2.25 to 3.77 | 8.23 to 14.41 | −1.36 to 7.40 | |
Denotes a significant effect (p < 0.017); BD, Baduanjin group; CG, control group; Pre, pretest; 8 post, 8th post assessment; 12 post, 12th post assessment.
Results of outcome variables with post-hoc analysis between two groups.
| OPAP (mm) | 0.579 | 0.528 | |
| 95% CI | −0.59 to 0.92 | −1.33 to 0.69 | |
| OPML (mm) | 0.668 | 0.498 | |
| 95% CI | −0.68 to 0.44 | −1.90 to 0.94 | |
| CPAP (mm) | 0.047 | 0.001 | |
| 95% CI | −1.19 to −0.01 | −1.88 to 0.52 | |
| CPML (mm) | 0.267 | 0.035 | |
| 95% CI | −1.79 to −0.51 | −1.62 to −0.06 | |
| TTE (s) | 0.157 | 0.001 | |
| 95% CI | −11.70 to 1.94 | −12.44 to 4.52 | |
| ATE (%) | 0.001 | 0.029 | |
| 95% CI | −28.74 to −11.14 | −20.48 to −1.12 | |
| Overall | 0.001 | 0.001 | |
| WOMAC | 95% CI | −16.03 to −4.13 | −17.95 to −9.57 |
| Pain | 0.001 | 0.325 | |
| 95% CI | −4.73 to −2.47 | −3.75 to 1.27 | |
| Stiffness | 0.001 | 0.001 | |
| 95% CI | −6.16 to −3.76 | −5.07 to −3.09 | |
| Physical function | 0.587 | 0.001 | |
| 95% CI | −6.36 to 3.64 | −10.38 to −3.06 |
Denotes a significant effect (p < 0.025). 8 post, 8th post assessment; 12 post, 12th post assessment.